Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

[1]  Philippe Van De Borne,et al.  Guidelines for the management of arterial hypertension , 2014 .

[2]  J. Staessen,et al.  Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations , 2011, Hypertension Research.

[3]  W. Ghali,et al.  Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies , 2011, BMJ : British Medical Journal.

[4]  W. Ghali,et al.  Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis , 2011, BMJ : British Medical Journal.

[5]  G. Bakris,et al.  Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. , 2010, JAMA.

[6]  J. Tuomilehto,et al.  The Difference between Acute Coronary Heart Disease and Ischaemic Stroke Risk with Regard to Gender and Age in Finnish and Swedish Populations , 2010, International journal of stroke : official journal of the International Stroke Society.

[7]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[8]  S. Yusuf,et al.  Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study , 2009, Journal of hypertension.

[9]  G. Mancia,et al.  When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal , 2009, Journal of hypertension.

[10]  D. Levy,et al.  Single Versus Combined Blood Pressure Components and Risk for Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.

[11]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[12]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[13]  Sonia S. Anand,et al.  Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. , 2008, European heart journal.

[14]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[15]  P. Ponikowski,et al.  Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II , 2008, European journal of heart failure.

[16]  S. Willich,et al.  An update on regional variation in cardiovascular mortality within Europe. , 2007, European heart journal.

[17]  V. Basevi.  Standards of medical care in diabetes--2007. , 2009, Diabetes care.

[18]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[19]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[20]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[21]  S. Larsson,et al.  Alcoholic beverage consumption and gastric cancer risk: A prospective population‐based study in women , 2007, International journal of cancer.

[22]  Fei Tan.  A method for finding the nadir of non-monotonic relationships , 2007 .

[23]  S. Glaser,et al.  Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors , 2006, BMC Cancer.

[24]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[25]  P. Kowey,et al.  Predictors of adverse outcome among patients with hypertension and coronary artery disease. , 2006, Journal of the American College of Cardiology.

[26]  David V. Power,et al.  Standards of Medical Care in Diabetes: Response to position statement of the American Diabetes Association , 2006 .

[27]  W. Elliott.  Effects of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus: Results of Prospectively Designed Overviews of Randomized Trials , 2006 .

[28]  Neil Chapman,et al.  Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. , 2005, Archives of internal medicine.

[29]  S. Yusuf,et al.  Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Int , 2004, American heart journal.

[30]  H. Keen,et al.  Incidence of macrovascular disease in diabetes mellitus: the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics , 1991, Diabetologia.

[31]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[32]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[33]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[34]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[35]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[36]  Y. Uehara.  The world of endothelin in the brain of the stroke-prone spontaneously hypertensive rat. , 2003, Journal of hypertension.

[37]  François Gueyffier,et al.  J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data , 2002, Annals of Internal Medicine.

[38]  P. Mehler,et al.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.

[39]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[40]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[41]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[42]  H. Tunstall-Pedoe,et al.  Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. , 1999, Lancet.

[43]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[44]  J. Neaton,et al.  Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). , 1998, International journal of epidemiology.

[45]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[46]  G. Bakris.  Progression of diabetic nephropathy. A focus on arterial pressure level and methods of reduction. , 1998, Diabetes research and clinical practice.

[47]  K. Asplund,et al.  Diabetes as a risk factor for myocardial infarction: population and gender perspectives , 1997, Journal of internal medicine.

[48]  M. Guazzi,et al.  Upward Shift of the Lower Range of Coronary Flow Autoregulation in Hypertensive Patients With Hypertrophy of the Left Ventricle , 1991, Circulation.